Clinical Trial Update: Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial of QGE031 as add-on therapy for chronic spontaneous urticaria has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• QGE031

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2018-09-14